A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia Naftopidil versus Tamsulosin with Solifenacin

A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia : Naftopidil versus Tamsulosin with Solifenacin

We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolle...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 62(2016), 7 vom: 15. Juli, Seite 341-7
1. Verfasser: Utsunomiya, Noriaki (VerfasserIn)
Weitere Verfasser: Matsumoto, Keiyu, Tsunemori, Hiroyuki, Muguruma, Koei, Kawakita, Mutsushi, Kamiyama, Yuki, Kanamaru, Sojun, Ito, Noriyuki, Tsukazaki, Hideki, Shirahase, Toshiaki, Takahashi, Takeshi
Format: Online-Aufsatz
Sprache:Japanese
Veröffentlicht: 2016
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Comparative Study Journal Article Randomized Controlled Trial Adrenergic alpha-Antagonists Muscarinic Antagonists Naphthalenes Piperazines Sulfonamides Tamsulosin G3P28OML5I mehr... Solifenacin Succinate KKA5DLD701 naftopidil R9PHW59SFN
LEADER 01000caa a22002652 4500
001 NLM263828646
003 DE-627
005 20250220142527.0
007 cr uuu---uuuuu
008 231224s2016 xx |||||o 00| ||jpn c
024 7 |a 10.14989/ActaUrolJap_62_7_341  |2 doi 
028 5 2 |a pubmed25n0879.xml 
035 |a (DE-627)NLM263828646 
035 |a (NLM)27569351 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a jpn 
100 1 |a Utsunomiya, Noriaki  |e verfasserin  |4 aut 
245 1 2 |a A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia  |b Naftopidil versus Tamsulosin with Solifenacin 
264 1 |c 2016 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 13.01.2017 
500 |a Date Revised 02.12.2018 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a We compared the efficacy of naftopidil monotherapy with combination therapy using tamsulosin hydrochloride and solifenacin succinate in the treatment of lower urinary tract symptoms (LUTS) with overactive bladder (OAB) secondary to benign prostatic hyperplasia (BPH). Thirty one patients were enrolled in a randomized crossover study. Fourteen patients were initially prescribed naftopidil 75 mg (N) for 8 weeks, followed by tamsulosin 0.2 mg and solifenacin 5 mg (TS) for 8 weeks (group N) ; another 17 were initially prescribed TS, followed by N (group TS). The efficacy variables were the changes in international prostate symptom score (I-PSS), quality of life (QOL) score, overative bladder symptom score (OABSS), and post-void residual (PVR) urine volume. After the study, a questionnaire survey was carried out about the choice of treatment. After treatment with each agent, total I-PSS, storage symptom score, QOL score and OABSS except for the daytime frequency were significantly improved from baseline. PVR was significantly increased after TS treatment. There were no significant differences between the two treatments except for PVR. As a result of the questionnaire survey, 13 patients chose N and 17 chose TS. In conclusion, N monotherapy can be expected to have an equal effect in the treatment of LUTS with OAB secondary to BPH in comparison with TS combination therapy 
650 4 |a Comparative Study 
650 4 |a Journal Article 
650 4 |a Randomized Controlled Trial 
650 7 |a Adrenergic alpha-Antagonists  |2 NLM 
650 7 |a Muscarinic Antagonists  |2 NLM 
650 7 |a Naphthalenes  |2 NLM 
650 7 |a Piperazines  |2 NLM 
650 7 |a Sulfonamides  |2 NLM 
650 7 |a Tamsulosin  |2 NLM 
650 7 |a G3P28OML5I  |2 NLM 
650 7 |a Solifenacin Succinate  |2 NLM 
650 7 |a KKA5DLD701  |2 NLM 
650 7 |a naftopidil  |2 NLM 
650 7 |a R9PHW59SFN  |2 NLM 
700 1 |a Matsumoto, Keiyu  |e verfasserin  |4 aut 
700 1 |a Tsunemori, Hiroyuki  |e verfasserin  |4 aut 
700 1 |a Muguruma, Koei  |e verfasserin  |4 aut 
700 1 |a Kawakita, Mutsushi  |e verfasserin  |4 aut 
700 1 |a Kamiyama, Yuki  |e verfasserin  |4 aut 
700 1 |a Kanamaru, Sojun  |e verfasserin  |4 aut 
700 1 |a Ito, Noriyuki  |e verfasserin  |4 aut 
700 1 |a Tsukazaki, Hideki  |e verfasserin  |4 aut 
700 1 |a Shirahase, Toshiaki  |e verfasserin  |4 aut 
700 1 |a Takahashi, Takeshi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Hinyokika kiyo. Acta urologica Japonica  |d 1962  |g 62(2016), 7 vom: 15. Juli, Seite 341-7  |w (DE-627)NLM012631779  |x 0018-1994  |7 nnns 
773 1 8 |g volume:62  |g year:2016  |g number:7  |g day:15  |g month:07  |g pages:341-7 
856 4 0 |u http://dx.doi.org/10.14989/ActaUrolJap_62_7_341  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_40 
912 |a GBV_ILN_60 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_350 
912 |a GBV_ILN_2001 
912 |a GBV_ILN_2003 
912 |a GBV_ILN_2005 
912 |a GBV_ILN_2006 
912 |a GBV_ILN_2008 
912 |a GBV_ILN_2010 
912 |a GBV_ILN_2012 
912 |a GBV_ILN_2018 
951 |a AR 
952 |d 62  |j 2016  |e 7  |b 15  |c 07  |h 341-7